Recombinant Mouse FGL2 Protein, N-His from ProteoGenix; catalogue ARO-P11120; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Recombinant Mouse FGL2 Protein, also known as fibrinogen-like protein 2, is a type of recombinant protein that has been produced through genetic engineering techniques. This protein is derived from the mouse FGL2 gene and has been extensively studied for its structure, activity, and potential applications in various fields of research. In this article, we will delve into the details of Recombinant Mouse FGL2 Protein and its significance in the scientific community.
Recombinant Mouse FGL2 Protein is a glycoprotein that consists of 337 amino acids and has a molecular weight of approximately 38 kDa. It is composed of three distinct domains: an N-terminal domain, a central domain, and a C-terminal domain. The N-terminal domain contains a signal peptide that is responsible for the secretion of the protein from the cell. The central domain is the largest and contains a highly conserved fibrinogen-like domain, which is responsible for the binding of the protein to fibrinogen and other ligands. The C-terminal domain is the smallest and contains a putative serine protease domain, which is believed to be involved in the proteolytic activity of FGL2.
Recombinant Mouse FGL2 Protein has been found to have various activities, including immunomodulatory, anticoagulant, and antiviral activities. The immunomodulatory activity of this protein is attributed to its ability to inhibit the activity of T cells and natural killer cells, thus suppressing the immune response. This activity has been studied extensively in the context of autoimmune diseases and organ transplantation, where FGL2 has been shown to play a crucial role in regulating immune tolerance. Additionally, Recombinant Mouse FGL2 Protein has been found to have anticoagulant activity by inhibiting the conversion of fibrinogen to fibrin, thereby preventing blood clot formation. This activity has been studied in the context of thrombotic disorders and has shown promising results in preclinical studies. Furthermore, FGL2 has been found to have antiviral activity by inhibiting the replication of certain viruses, including hepatitis C virus and human immunodeficiency virus (HIV).
Recombinant Mouse FGL2 Protein has numerous potential applications in the fields of immunology, hematology, and virology. In immunology, this protein has been studied for its role in immune tolerance and has shown promising results in the treatment of autoimmune diseases and prevention of organ rejection in transplantation. In hematology, FGL2 has been studied for its anticoagulant activity and has shown potential as a therapeutic agent for thrombotic disorders. Moreover, Recombinant Mouse FGL2 Protein has been studied for its antiviral activity and has shown potential as a treatment for viral infections, particularly in the case of hepatitis C and HIV. Additionally, FGL2 has been studied in cancer research as it has been found to be overexpressed in certain types of cancer, and its inhibition has shown promising results in preclinical studies.
In conclusion, Recombinant Mouse FGL2 Protein is a glycoprotein with a complex structure and diverse activities. Its role in regulating immune tolerance, inhibiting blood clot formation, and suppressing viral replication has garnered significant interest in the scientific community. With its potential applications in various fields of research, Recombinant Mouse FGL2 Protein holds promise as a therapeutic agent for various diseases and disorders. Further studies and clinical trials are needed to fully understand the potential of this protein and its implications in the field of medicine.
ProteoGenix catalogue number ARO-P11120. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 29.55 kDa; Fragment: His200-Pro432; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
